Access the full text.
Sign up today, get DeepDyve free for 14 days.
G Pappas, IJ Kiriaze, ME Falagas (2008)
Insights into infectious disease in the era of HippocratesInt J Infect Dis, 12
RA Bright, KM Neuzil, Y Pervikov, L Palkonyay (2009)
WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008Vaccine, 27
PM Martin, E Martin-Granel (2006)
2500-year evolution of the term epidemicEmerg Infect Dis, 12
RL Malby, WR Tulip, VR Harley (1994)
The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibodyStruct Lond Engl, 2
A Monto, A Kendal (1973)
Effect of neuraminidase antibody on hong kong influenzaLancet, 301
F Behzadian, Z Goodarzi, F Fotouhi, E Saberfar (2013)
Baculoviral co-expression of HA, NA and M1 proteins of highly pathogenic H5N1 influenza virus in insect cellsJundishapur J Microbiol
H Wan, H Yang, DA Shore (2015)
Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomersNat Commun, 6
ED Kilbourne, RB Couch, JA Kasel (1995)
Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humansVaccine, 13
BJ Bosch, R Bodewes, RP Vries (2010)
Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferretsJ Virol, 84
T Han, WA Marasco (2011)
Structural basis of influenza virus neutralizationAnn N Y Acad Sci, 1217
H Ding, C Tsai, F Zhou (2011)
Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virusPLoS One, 6
H Song, V Wittman, A Byers (2010)
In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccineVaccine, 28
RB Couch, RL Atmar, LM Franco (2013)
Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidaseJ Infect Dis, 207
P Shil, SS Chavan, SS Cherian (2011)
Antigenic variability in Neuraminidase protein of Influenza A/H3N2 vaccine strains (1968–2009)Bioinformation, 7
JL Schulman, M Khakpour, ED Kilbourne (1968)
Protective effects of specific immunity to viral neuraminidase on influenza virus infection of miceJ Virol, 2
IC Brett, BE Johansson (2005)
Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model systemVirology, 339
L Couzens, J Gao, K Westgeest (2014)
An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human seraJ Virol Methods, 210
RA Bright, DM Carter, S Daniluk (2007)
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutininVaccine, 25
PM Colman (1994)
Influenza virus neuraminidase: structure, antibodies, and inhibitorsProtein Sci, 3
E Garman, G Laver (2005)
Viral Membrane Proteins: Structure, Function, and Drug Design
L Venkatramani, E Bochkareva, JT Lee (2006)
An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complexJ Mol Biol, 356
F-S Quan, M-C Kim, B-J Lee (2012)
Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protectionVirology, 430
TM Doyle, AM Hashem, C Li (2013)
Universal anti-neuraminidase antibody inhibiting all influenza A subtypesAntiviral Res, 100
TL Williams, JL Pirkle, JR Barr (2012)
Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometryVaccine, 30
MR Sandbulte, KB Westgeest, J Gao (2011)
Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza virusesProc Natl Acad Sci, 108
S Tong, Y Li, P Rivailler (2012)
A distinct lineage of influenza A virus from batsProc Natl Acad Sci, 109
X Xu, X Zhu, RA Dwek (2008)
Structural characterization of the 1918 influenza virus H1N1 neuraminidaseJ Virol, 82
MN Matrosovich, TY Matrosovich, T Gray (2004)
Neuraminidase is important for the initiation of influenza virus infection in human airway epitheliumJ Virol, 78
WR Tulip, JN Varghese, WG Laver (1992)
Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complexJ Mol Biol, 227
C-Y Wu, Y-C Yeh, J-T Chan (2012)
A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virusPLoS One, 7
TJ Wohlbold, R Nachbagauer, H Xu (2015)
Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in micemBio, 6
BE Johansson, DJ Bucher, ED Kilbourne (1989)
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infectionJ Virol, 63
MC Creskey, C Li, J Wang (2012)
Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC–MSEVaccine, 30
GE Smith, DC Flyer, R Raghunandan (2013)
Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virusVaccine, 31
S-M Kang, D-G Yoo, AS Lipatov (2009)
Induction of long-term protective immune responses by influenza H5N1 virus-like particlesPLoS One, 4
BE Johansson, TM Moran, ED Kilbourne (1987)
Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteinsProc Natl Acad Sci USA, 84
E Takashita, A Meijer, A Lackenby (2015)
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014Antiviral Res, 117
GM Air (2012)
Influenza neuraminidase: influenza neuraminidaseInfluenza Other Respir Viruses, 6
BE Johansson, BA Pokorny, VA Tiso (2002)
Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competitionVaccine, 20
JJ Skehel, DC Wiley (2000)
Receptor binding and membrane fusion in virus entry: the influenza hemagglutininAnnu Rev Biochem, 69
KB Westgeest, CA Russell, X Lin (2014)
Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011J Virol, 88
U Gulati, C-C Hwang, L Venkatramani (2002)
Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98)J Virol, 76
I Sultana, K Yang, M Getie-Kebtie (2014)
Stability of neuraminidase in inactivated influenza vaccinesVaccine, 32
F Zhang, J Chen, F Fang (2005)
Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult miceDNA Cell Biol, 24
T Wohlbold, F Krammer (2014)
In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigenViruses, 6
JL McKimm-Breschkin (2013)
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceInfluenza Other Respir Viruses, 7
RB Couch, RL Atmar, WA Keitel (2012)
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccinesVaccine, 31
S Tong, X Zhu, Y Li (2013)
New world bats harbor diverse influenza A virusesPLoS Pathog, 9
Z Chen, K Matsuo, H Asanuma (1999)
Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAsVaccine, 17
M Hocart, B Grajower, A Donabedian (1995)
Preparation and characterization of a purified influenza virus neuraminidase vaccineVaccine, 13
S-M Kang, J-M Song, F-S Quan, RW Compans (2009)
Influenza vaccines based on virus-like particlesVirus Res, 143
M Getie-Kebtie, I Sultana, M Eichelberger, M Alterman (2013)
Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines: label-free mass spectrometry-based quantification of HAInfluenza Other Respir Viruses, 7
Y Abed, I Hardy, Y Li, G Boivin (2002)
Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A: H3N2 viruses isolated in CanadaJ Med Virol, 67
CJ Vavricka, Q Li, Y Wu (2011)
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group Specific mechanisms for influenza NA inhibitionPLoS Pathog, 7
DM Knipe, PM Howley (2007)
Fields’ virology
JN Varghese, WG Laver, PM Colman (1983)
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolutionNature, 303
ED Kilbourne, BA Pokorny, B Johansson (2004)
Protection of mice with recombinant influenza virus neuraminidaseJ Infect Dis, 189
Influenza, the most common infectious disease, poses a great threat to human health because of its highly contagious nature and fast transmissibility, often leading to high morbidity and mortality. Effective vaccination strategies may aid in the prevention and control of recurring epidemics and pandemics associated with this infectious disease. However, antigenic shifts and drifts are major concerns with influenza virus, requiring effective global monitoring and updating of vaccines. Current vaccines are standardized primarily based on the amount of hemagglutinin, a major surface antigen, which chiefly constitutes these preparations along with the varying amounts of neuraminidase (NA). Anti-influenza drugs targeting the active site of NA have been in use for more than a decade now. However, NA has not been approved as an effective antigenic component of the influenza vaccine because of standardization issues. Although some studies have suggested that NA antibodies are able to reduce the severity of the disease and induce a long-term and cross-protective immunity, a few major scientific issues need to be addressed prior to launching NA-based vaccines. Interestingly, an increasing number of studies have shown NA to be a promising target for future influenza vaccines. This review is an attempt to consolidate studies that reflect the strength of NA as a suitable vaccine target. The studies discussed in this article highlight NA as a potential influenza vaccine candidate and support taking the process of developing NA vaccines to the next stage.
Archives of Virology – Springer Journals
Published: Jun 2, 2016
Access the full text.
Sign up today, get DeepDyve free for 14 days.